Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2002

View Archived Issues

Ilex sublicenses CD52 diagnostic rights to Ventana

Novel alphav integrin antagonists and their use in osteoporosis

Vanilloid VR1 antagonists identified at GSK

Merck & Co. synthesizes new alpha2/alpha3-selective GABA-A agonist

Gruenenthal presents novel opioid agents for diarrhea, IBS, pain and immunomodulation

Tetracyclic MCH receptor modulators identified by Tularik scientists

Phase I testing of ACP-HIP cleared to begin by Health Canada

Two series of azole-based antifungal agents prepared and tested at Aventis

New caspase activators in Cytovia development pipeline

RenaZorb begins testing in animals

Thuris to evaluate CNCDS's compounds in antiaging and Alzheimer's models

European approval for room-temperature storage of Betaferon

Vectura and GSK sign dry powder drug formulation agreement

AMD-3100 shows potential in myocardial infarction and for CD34+ cell mobilization/collection

Apomine as a new therapeutic approach to multiple myeloma

NanoCarrier and Kirin collaborate on anticancer therapeutics

Phase I testing of Abiogen's OGP drug to begin in Italy

CTCE-0021 rapidly mobilizes PMNs and hematopoietic progenitor cells

Nastech's intranasal morphine product shows rapid absorption and good pain relief

Pharmacokinetic studies in monkeys suggest feasibility of s.c. administration of PRO-38747

Exherin cleared to enter phase I trials in Canada

NeoTherapeutics renamed Spectrum Pharmaceuticals

CTA filed in Europe for MDX-018 in autoimmune indication

Inhibition of Src tyrosine kinases as a novel approach to the treatment of CML

Treatment begins in phase II trial of myoblast cell transplantation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.